

This patient group direction (PGD) must only be used by registered health professionals who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version of the PGD should be used.

Patient Group Direction (PGD)

For the administration or supply of

Co-codamol 30/500mg tablet/caplet/effervescent

By registered health care professionals for

Acute moderate pain

Throughout the Manx Care and those contracted by the Manx Care where appropriate within practice

PGD NUMBER 97

1. Change history

Version number	Change details	Date
1	Original PGD ratified	June 2021
2	Minor word changes to ensure clarify of PGD and links added to Cautions and Adverse Effects, and reference to Manx Care Policy for Capacity added. Plus: <ul style="list-style-type: none"> • Cautions updated • Amendments make to Exclusion criteria • CD schedule 5 added to Legal Category 	Nov 2023

2. Medicines practice guideline 2: *Patient group directions*

Refer to the relevant sections of NICE medicines practice guideline 2: *Patient group directions* as stated in the blank template notes. For further information about PGD signatories, see the NHS and Manx Care [PGD website FAQs](#).

3. PGD development

Refer to the [NICE PGD competency framework for people developing PGDs](#)

Job Title & organisation	Name	Signature	Date
Author of the PGD			
Member of the PGD working group			

4. PGD authorisation

Refer to the [NICE PGD competency framework for people authorising PGDs](#)

Pre Signatures			
Job Title	Name	Signature	Date
Chief Pharmacist/ Pharmaceutical Adviser			
Head of Ambulance Services			
GP Adviser			
Senior Microbiologist (if PGD contains antimicrobials)	N/A	N/A	N/A
Final signatures			
Medical Director			
Director of Nursing			

5. Training and competency of registered healthcare professionals, employed or contracted by the Manx Care, GP practice or Hospice

Refer to the [NICE PGD competency framework for health professionals using PGDs](#)

	Requirements of registered Healthcare professionals working under the PGD
Qualifications and professional registration	<ul style="list-style-type: none"> Registered healthcare professionals, working within or contracted by the Manx Care, GP practice or Hospice who are permitted staff groups outlined within the current PGD policy Pharmacists must be practising in Manx Care authorised premises i.e. contracted pharmacy premises
Initial training	<ul style="list-style-type: none"> Knowledge of current guidelines and the administration of the drug specified in this PGD/BNF and of the inclusion and exclusion criteria Training which enables the practitioner to make a clinical assessment to establish the need for the medication covered by this PGD Local training in the use of PGDs
Competency assessment	Staff will be assessed on their knowledge of drugs and clinical assessment as part the competency framework for registered health professionals using PGDs
Ongoing training and competency	The registered health care professionals should make sure they are aware of any changes to the recommendations for this medication; it is the responsibility of the registered health care professionals to keep up to date with continuing professional development. PGD updates will be held every two years

6. Clinical Conditions

Clinical condition or situation to which this PGD applies	Acute moderate pain
Inclusion criteria	<ul style="list-style-type: none"> Over the age of 12 years Patients presenting with acute moderate pain
Exclusion criteria <i>(continued ...)</i>	<ul style="list-style-type: none"> Children under age 12 Allergy and hypersensitivity to Codeine or Paracetamol Acute colitis Antibiotic associated colitis Acute respiratory depression Acute asthma/COPD Breastfeeding Conditions where peristalsis may be impaired Conditions where abdominal distension develops Head injury/raised ICP Hypothyroidism Hypotension (systolic <100mmHg) Inflammatory or obstructive bowel disorders

Exclusion criteria <i>(... continued)</i>	<ul style="list-style-type: none"> • Risk of paralytic ileus • Third trimester of pregnancy • When using other opiate based medicines
Cautions (including any relevant action to be taken)	<ul style="list-style-type: none"> • Patients under 50kg • Patients who are pregnant • Asthma/COPD • Biliary tract disease • Cardiac arrhythmias • Chronic malnutrition or dehydration • Convulsive disorders • Hepatocellular insufficiency • History of alcohol dependence, or chronic alcoholism • History of drug addiction or those currently prescribed Naltrexone • Inflammatory bowel disorders, and obstructive bowel disorders • Marked increase in morphine toxicity in patients who are ultra-rapid codeine metabolisers (CYP2D6 Ultra Rapid Metabolisers) • Myasthenia gravis • Prostatic hypertrophy • Reduced therapeutic effect in poor codeine metabolisers • Shock • Urethral stenosis <p>MHRA advice: Caution should be taken as to prescribing opioid analgesics in patients prescribed benzodiazepines</p> <p>A detailed list of cautions is available in the SPC, which is available from the electronic Medicines Compendium website: www.medicines.org.uk and BNF https://bnf.nice.org.uk</p>
Arrangements for referral for medical advice	Patient should be referred to a more experienced clinical practitioner for further assessment
Action to be taken if patient excluded	Patient should be referred to a more experienced clinical practitioner for further assessment
Action to be taken if patient declines treatment	<ul style="list-style-type: none"> • A verbal explanation should be given to the patient on: the need for the medication and any possible effects or potential risks which may occur as a result of refusing treatment • This information must be documented in the patients' health records • Any patient who declines care must have demonstrated capacity to do so (see the Manx Care Policy for Capacity, Best Interests Decisions and Deprivation of Liberty) • Where appropriate care should be escalated

7. Details of the medicine

Name, form and strength of medicine	Co-Codamol 30/500mg tablet/capsule/effervescent
Legal category	<ul style="list-style-type: none"> • Prescription Only Medicine (POM) • CD schedule 5
Indicate any <u>off-label use</u> (if relevant)	None
Route/method of administration	Oral
Dose and frequency	<ul style="list-style-type: none"> • Persons under 50kg ... One tablet/caplet/effervescent • Persons 50kg or over ... Two tablets/caplets/effervescent every four to six hours when required
Quantity to be administered and/or supplied	<ul style="list-style-type: none"> • Administered as per dose and frequency • Supplied one original pack
Maximum or minimum treatment period	<ul style="list-style-type: none"> • Persons under 50kg - Maximum 4 tablets/caplets/effervescent in 24 hours • Persons 50kg or over - No more than 8 tablets/caplets/effervescent in 24 hours
Storage	<ul style="list-style-type: none"> • Do not store above 25°C • Store in the original container
Adverse effects	<ul style="list-style-type: none"> • Arrhythmias • Confusion • Constipation • Dizziness • Drowsiness • Dry mouth • Euphoric mood • Flushing • Hallucination • Headache • Hyperhidrosis • Hypotension (with high doses) • Miosis • Nausea (more common on initiation) • Palpitations • Respiratory depression (with high doses) • Skin reactions • Urinary retention • Vertigo • Visual impairment • Vomiting (more common on initiation) • Withdrawal syndrome <p>A detailed list of adverse reactions is available in the SPC, which is available from the electronic Medicines Compendium website: www.medicines.org.uk and BNF https://bnf.nice.org.uk</p>
Records to be kept	The administration of any medication given under a PGD must be recorded within the patient's medical records

8. Patient information

Verbal/Written information to be given to patient or carer	<ul style="list-style-type: none">• Verbal information must be given to patients and or carers for all medication being administered under a PGD• Where medication is being supplied under a PGD, written patient information leaflet must also be supplied• A patient information leaflet is available on request• Patients should be advised to avoid driving and or operating heavy machinery should this medication cause drowsiness
Follow-up advice to be given to patient or carer	If symptoms do not improve or worsen or you become unwell, seek medical advice immediately

9. Appendix A

References
<ol style="list-style-type: none">1. British National Formulary (BNF) available online: https://bnf.nice.org.uk2. Nursing and Midwifery “The code” available online: https://www.nmc.org.uk3. Current Health Care Professions Council standards of practice4. General Pharmaceutical Council standards5. Electronic medicines compendium available online: https://www.medicines.org.uk6. Manx Care Policy for Capacity, Best Interests Decisions and Deprivation of Liberty http://edrmgi/sites/hospital/Clinical%20Policies%20and%20Procedures/Policy%20for%20Capacity,%20Best%20Interests%20Decisions%20and%20Deprivation%20of%20Liberty.pdf#search=deprivation

10. Appendix B

Health professionals agreed to practice
<ul style="list-style-type: none">• Each registered healthcare professional will hold their own Competency framework which will be signed and agreed by their mentor• A mentor is defined within the Manx Care policy as any ward/area managers, sisters, senior nurses, GPs, pharmacists or senior paramedics who has completed the PGD training themselves